Sector News

Becton Dickinson to buy CareFusion for $12bn

October 8, 2014
Life sciences

Medical devices giant Becton Dickinson (BD) has agreed to buy automation and infection prevention specialist CareFusion for over $12 billion (£7.5 billion) in a mixture of shares and borrowed cash.

CareFusion develops technology for reducing drug dispensing errors by automation, and for preventing and detecting infections.

BD says that Carefusion’s products are complementary to its own ranges, and its distribution infrastructure will allow the merged company to increase global sales and cut supply chain costs.

The move follows other consolidation between major players in the medical devices segment, including Medtronic’s $43 billion purchase of Covidien in June.

Source: Chemistry World

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach